diphenyl-1-pyrenylphosphine has been researched along with amlodipine in 1 studies
| Studies (diphenyl-1-pyrenylphosphine) | Trials (diphenyl-1-pyrenylphosphine) | Recent Studies (post-2010) (diphenyl-1-pyrenylphosphine) | Studies (amlodipine) | Trials (amlodipine) | Recent Studies (post-2010) (amlodipine) |
|---|---|---|---|---|---|
| 22 | 1 | 7 | 4,200 | 1,504 | 1,671 |
| Protein | Taxonomy | diphenyl-1-pyrenylphosphine (IC50) | amlodipine (IC50) |
|---|---|---|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C | Cavia porcellus (domestic guinea pig) | 1.2 | |
| Potassium channel subfamily K member 2 | Homo sapiens (human) | 0.4 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.602 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 1.8 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 2.898 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 5.521 | |
| Voltage-dependent L-type calcium channel subunit alpha-1C | Homo sapiens (human) | 2.7 | |
| Potassium channel subfamily K member 2 | Bos taurus (cattle) | 0.43 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujitani, Y; Hirose, T; Kanazawa, A; Kawamori, R; Ohmura, C; Sakai, K; Shimizu, T; Uchino, H; Watada, H | 1 |
1 trial(s) available for diphenyl-1-pyrenylphosphine and amlodipine
| Article | Year |
|---|---|
Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Ascorbic Acid; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropyridines; Erythrocytes; Female; Humans; Hypertension; Lipid Peroxides; Male; Middle Aged; Organophosphorus Compounds; Pyrenes; Vitamin E | 2007 |